Randomized trial · people

Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In adults with MASH and stage 2-3 scarring, efinopegdutide cleared MASH in far more people than placebo over a year, and side effects were most common at 10 mg.

Kind
Randomized trial
Studied in
People
Number studied
381
Published
2026
Journal
Lancet

What they tested

The team tested whether weekly efinopegdutide could clear MASH and reduce liver scarring in adults without cirrhosis, compared with placebo.

How the study was done

A phase 2b, randomized, double-blind, placebo-controlled trial at 176 centers in 26 countries. Of 386 adults randomized, 381 received at least one dose. All had biopsy-confirmed MASH (fatty liver with inflammation) and stage 2 or stage 3 fibrosis (scarring). They got weekly shots of efinopegdutide 4 mg, 7 mg or 10 mg, placebo (a dummy shot), or open-label semaglutide 2.4 mg for 52 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 52, MASH went away without fibrosis getting worse in 31 of 55 people (56%) in the 4 mg arm, 31 of 49 (63%) in the 7 mg arm and 35 of 57 (61%) in the 10 mg arm, compared with 7 of 53 (13%) on placebo. Gaps versus placebo were 43.0, 49.5 and 47.8 percentage points, all p<0.0001. On semaglutide, 26 of 49 (53%) met this goal. Fibrosis improved by at least one stage without worse inflammation in 43% (4 mg), 52% (7 mg) and 34% (10 mg) versus 21% on placebo. The 10 mg result did not reach statistical significance (p=0.072). Gut side effects were the most common, and they were highest at 10 mg. At 10 mg, 11% stopped treatment due to side effects, versus 3-4% at the lower doses and 1% on placebo.

What it doesn’t show

This was a mid-stage trial that lasted 1 year. It does not show longer-term liver outcomes. The semaglutide arm was open-label, and the trial was funded by Merck Sharp & Dohme.

The paper

Lawitz et al. Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. Lancet. 2026.

The compound

More studies on Efinopegdutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo